CooperSurgical (COO)

Executive Summary

CooperSurgical, a subsidiary of The Cooper Companies, is a leading global medical device and diagnostics company focused on women's health and fertility. The company offers a comprehensive portfolio of products and services spanning reproductive care, fertility, birth, and gynecological health, empowering healthcare providers to improve patient outcomes. With a strong market presence and over 30 years of innovation, CooperSurgical is well-positioned to capitalize on growing demand for fertility treatments and minimally invasive gynecological procedures. The company benefits from its parent's financial strength and global distribution network, driving consistent revenue growth and expanding its addressable market through internal development and strategic acquisitions. Key growth drivers include the launch of next-generation IVF culture media and diagnostic tests, as well as expansion into emerging markets. While competition from players like Merck and Thermo Fisher remains, CooperSurgical's specialized focus and integrated solutions provide a competitive edge. The company's recent investments in R&D and commercial infrastructure are expected to sustain its leadership in the rapidly evolving women's health sector.

Upcoming Catalysts (preview)

• Q3 2026FDA Clearance for Next-Generation IVF Culture Media70% success
• Q3 2026Launch of Novel Surgical Device for Minimally Invasive Gynecology60% success
• TBDAcquisition of a Fertility Diagnostics Company50% success